Michael U Callaghan
Overview
Explore the profile of Michael U Callaghan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Young G, Callaghan M, Balasa V, Soni A, Ahuja S, Roberts J, et al.
Haemophilia
. 2023 Aug;
29(5):1234-1242.
PMID: 37553998
Introduction: In recent years, there has been increased focus on individualizing treatment for persons with hemophilia including pharmacokinetic-guided (PK) dosing. Aims: In this retrospective study clinical outcomes before and after...
2.
Guzzardo G, Sidonio Jr R, Callaghan M, Regling K
Expert Opin Investig Drugs
. 2022 Oct;
31(11):1169-1186.
PMID: 36265129
Introduction: Hemophilia A is a severe bleeding disorder affecting about 1 in 5,000 males. The gold standard for prophylaxis and treatment of acute bleeding has been factor (F) VIII concentrate....
3.
Callaghan M, Asikanius E, Lehle M, Oldenburg J, Mahlangu J, Uguen M, et al.
Res Pract Thromb Haemost
. 2022 Sep;
6(6):e12782.
PMID: 36171959
Background: Bleeding in people with hemophilia A can be life threatening, and intra-articular bleeds can result in joint damage. Most clinical studies focus on treated bleeds, while bleeds not treated...
4.
Hulbert M, Manwani D, Meier E, Alvarez O, Brown R, Callaghan M, et al.
Pediatr Blood Cancer
. 2022 Sep;
70(1):e29961.
PMID: 36094289
Sickle cell disease (SCD) requires coordinated, specialized medical care for optimal outcomes. There are no United States (US) guidelines that define a pediatric comprehensive SCD program. We report a modified...
5.
Glaros A, Callaghan M, Smith W, Zaidi A
EJHaem
. 2022 Sep;
3(3):653-659.
PMID: 36051054
Evidence suggests neuropathic pain (NP) develops over time in sickle cell disease (SCD), contributing to a complex, difficult-to-treat phenotype, with management based on scant evidence. One characteristic of NP found...
6.
Peine B, Callaghan M, Callaghan J, Glaros A
J Clin Med
. 2022 Jun;
11(12).
PMID: 35743561
Sickle cell disease (SCD) increases the incidence of childhood stroke eighty-fold. Stroke risk can be estimated by measurement of the blood velocity through the middle cerebral artery (MCA) using transcranial...
7.
Regling K, Callaghan M, Sidonio Jr R
Pediatric Health Med Ther
. 2022 Feb;
13:27-35.
PMID: 35210899
Hemophilia A is the most common severe inherited bleeding disorder in males. Initial treatment strategies focused on the use of factor concentrates to prevent joint bleeding and the development of...
8.
White J, Callaghan M, Gao X, Liu K, Zaidi A, Tarasev M, et al.
Br J Haematol
. 2021 Dec;
196(4):1052-1058.
PMID: 34850378
Sickle cell disease (SCD) is characterized by frequent and unpredictable vaso-occlusive crises (VOCs). Sickle erythrocytes (SSRBCs) contribute to VOCs by participating in a series of adhesive events with blood cells...
9.
Hines P, Callaghan M, Zaidi A, Gao X, Liu K, White J, et al.
Br J Haematol
. 2021 Sep;
194(6):1074-1082.
PMID: 34472086
Blood cell adhesion to P-selectin and vascular cell adhesion molecule-1 (VCAM-1) contributes to the pathophysiology of vaso-occlusion crisis (VOC) events in individuals with sickle cell disease (SCD). We evaluated the...
10.
Skinner M, Negrier C, Paz-Priel I, Chebon S, Jimenez-Yuste V, Callaghan M, et al.
Haemophilia
. 2021 Jun;
27(5):854-865.
PMID: 34171159
Introduction: Severe haemophilia A (HA) has a major impact on health-related quality of life (HRQoL). Aim: Assess the impact of emicizumab on HRQoL in persons with severe HA (PwHA) without...